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Introduction
Breast cancer is the most common neoplasia both in 
the developed and developing countries. The incidence 
rates vary greatly worldwide from 19.3 per 100,000 in 
Eastern Africa, to 89.7 per 100,000 in Western Europe 
[1]. Although the lowest incidence rates of breast cancer 
are found in African countries, the incidence is increasing. 
In Nigeria, breast cancer occupies number 12th position 
among 20 causes of death in women [1]. Breast cancer 
survival rates also vary greatly among countries, ranging 
from 80% and over in Northern America, Sweden and 
Japan to around 60% in middle-income countries and 
below 40% in low-income countries [2-3]. The low 
survival rates in less developed countries are associated with inefective early detection programmes resulting in 
late presentation as well as the lack of adequate diagnosis 
and treatment facilities. 
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Abstract 
Background: Breast cancer markers are becoming increasingly important in breast cancer research due to their impact on prognosis, 
treatment and survival. The present retrospective study was carried out to quantify the proportion of estrogen (ER), progesterone 
(PR), and human epithelial receptor 2 (HER2) expressions and their association with tumour grade, age, and tumour size in breast 
cancer patients in Nigeria. Materials and methods: The paraffin embedded tissue sections were analysed for breast cancer markers 
using monoclonal antibody SP1 for ER and SP2 for PR and polyclonal antibody ErbB2 for HER2. Results: A total of 286 breast cancer paraffin wax tissue sections were analysed for ER, PR and HER2 expression. Of all the tissue samples examined, 20 (7%) were ER-
positive, 6 (2.1%) were PR-positive, 11 (3.8%) were HER2-positive whereas 248 (87%) were triple-negative breast carcinoma. ER- and 
PR-positivity was associated with early grade I and II tumours (P  0.010-0.009) and tumour sizes of  50mm (p  0.001). HER2-
positivity was positively (P  0.009) associated with grade II tumours and negatively (P  0.0001) associated with grade III tumours. 
Triple-negative breast cancer was associated with grade III tumours (P  0.0001) and larger tumour sizes of  50mm (P  0.0001). 
Conclusion: A small proportion of Nigerian women with breast cancer are ER/PR-positive which are associated with less aggressive, better prognosis and benefit from endocrine therapy. An even smaller proportion of patients with aggressive tumors were HER2-
posivite but responsive to Herceptin treatment. Unfortunately, a very high proportion of cases were triple-negative which is associated 
with very aggressive tumours and no targeted treatment, which may explain the high mortality rates from breast cancer in Nigeria.
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Open Access
The occurrence, progression and prognosis of breast 
cancer depend on complex processes involving various 
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genes, pathways and protein expression and regulation. 
Therefore it is difficult to determine the biological 
behaviour and prognosis of breast cancer based on the 
assessment of a single factor. Immunohistochemistry 
(IHC) has become essential to many malignancies and 
plays a key role in tumour diagnosis, treatment and 
prognosis assessment [4]. 
Several tumours are hormone-dependent and breast 
cancer is a typical example. Estrogen (ER) and 
progesterone (PR) play important roles in the growth and diferentiation of breast cancers making them important 
prognostic markers [5]. Human epithelial receptor 2 
(HER2), a proto-oncogene also known as ErbB2-neu, 
located on chromosome 17q21 is also considered to be 
closely associated with occurrence and development of 
breast cancer [6].Diferent expression patterns of ER, PR and HER2 have been identified, making knowledge of the receptor 
content of breast carcinoma essential in planning the 
management of disease [7-8]. ER over expression has 
been predominantly observed in lower grade, smaller 
size-tumours, more likely to be node negative, and 
shows better survival outcome than ER-negative cancers 
[7, 9-10]. PR over expression is also associated with well diferentiated tumours with good overall survival 
[11]. The over expression of ER is reported to occur in 
approximately 70-80% of invasive breast carcinoma at the 
point of diagnosis. Over expression of HER2 is associated 
with higher grade [12], and ER-negative tumours [13], 
which demonstrate poor overall survival [14]. The HER2 
over expression is reported to occur in 10-30% of invasive breast cancers [15]. Another subtype usually identified in breast cancer classification is the triple-negative. Triple-
negative breast cancers are tumours characterized by 
their lack of hormone receptors (ER and PR) and HER2. 
They are the most aggressive form and account for 10-
17% of all breast cancers [16]. 
The Lagos State University Teaching Hospital (LASUTH), 
Nigeria receives an average of 150 patients diagnosed with 
breast cancer annually. Majority of patients diagnosed 
with invasive breast carcinoma undergo surgery, followed 
by chemotherapy and radiotherapy as well as hormonal 
therapy.
In Nigeria, receptor status assessment for breast cancer 
patients is currently unavailable in many centers. However, 
tamoxifen is prescribed based on evidence suggesting 
that ER/ PR-positivity rates in Nigerians are the same 
as in Western countries [17]. Therefore, the aim of this study was first to carry out retrospective investigation to study the reliability of routinely processed paraffin wax 
sections in the assessment of ER, PR, and HER2 in a series 
of breast carcinomas. Second, to evaluate the association 
between ER-, PR-, HER2-positivity, and triple-negative 
tumours with other tumour characteristics including 
age at presentation, size of the tumour, and grade of the 
tumour.
Materials and methods
Data collection
Approved by the Faculty Research Board of Nigeria, the 
Lagos State University Teaching Hospital Cancer Registry 
was queried from 1 January 2009 to 31 December 2011 
and provided the following data on each invasive breast 
cancer subject: age, cancer site, tumour characteristics 
(morphology, grade, and size), and nodal disease status.Two hundred and eighty six formalin fixed, paraffin 
embedded tissue block samples from the breast lesions 
were investigated. Data related from the studied subjects 
were retrieved from Oncology Centre, LASUTH, Lagos, 
Nigeria. All samples were obtained from females with 
breast lesions, their ages ranging from 23 to 82 years with 
a mean age of 48.9 years old. 
Sample processing
Serial sections on HistoBond slides for 
Immunohistochemistry (IHC) and one section on a 
regular slide for haematoxylin and eosin (H&E) procedure 
were prepared for each case. The Immunohistochemistry 
staining was performed as per standard protocols. Briefly, slides were heated overnight at 60˚C, followed by deparaffinization in xylene and through graded ethyl alcohols and rehydration using the aqueous bufer. Before immunostaining with antibodies, the deparaffinized slides 
were incubated in 0.3% hydrogen peroxide in methanol 
for 20 min to inhibit endogenous peroxidise activity, then washed 3 times with IHC wash bufer (Bethyl Lab., UK). The tissues were subsequently treated with IHC retrieval bufer (PH 6.0) (Bethyl Lab., UK) at 96˚C for 20 
min for antigenic retrieval, and then washed 3 times with IHC wash bufer. Further slides were incubated in IHC blocking bufer (Bethyl Lab., UK) for 15 min to prevent non specific binding of antibodies. The IHC blocking 
agent was then drained and slides were incubated with 
the primary antibody for 1 h in a humidity chamber 
using the following dilutions: ER (clone SP1, titer 1:50, 
Abcam), PR (clone SP2, titer 1:50, Abcam), HER2/neu (ErbB2, titer 1:150, Bethyl Lab, UK). After rinsing the primary antibody thrice using IHC wash bufer for 5 min 
in each, the slides were incubated in secondary antibody labelled with HRP (Bethyl Lab., UK) for 1 h in the same 
chamber. Detection of labelled secondary antibody was detected using the DAB substrate ABC (Bethyl Lab., UK) 
according to manufacturer’s instructions. The sections 
were counter stained using haematoxylin, dehydrated 
using ethyl alcohol, cleared using xylene, and mounted in 
DPX then examined under light microscope. All sections 
were performed at the same time and submitted to standard methods. Known positive and negative cases 
were used as external controls. Two investigators 
evaluated the sections independently. Positive expression for each tumour marker was defined as in the literature: 
ER and PR, were considered positive when 10 of the nuclei were stained in 10 high power field (HPF) [18]. 
HER2/neu was considered negative when scored 0 and 
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1, positive with score 2 and 3. Cellular membrane 
should be completely stained in 10% tumour cells for 
it to be considered as 2, 3. Cells with no staining, or 
weak staining in part of the cell membrane and in 10% 
of the tumour cells were considered negative [19]. 
Statistical analysis
SPSS Software version 17.0 was used for all statistical 
analysis and p-value of 0.05 or less was regarded as statistically significant. Diferences in subjects and 
tumour characteristics between the various breast cancer 
subtypes were analysed using analysis of variance for 
continuous variables and Chi-square test for categorical 
variables.
Ethical consent
The studied protocol was submitted and approved by the 
Faculty Research Board of Nigeria in Collaboration with 
the Department of Pathology and Forensic Medicine, 
Lagos state Teaching Hospital, Nigeria.
ResultsTwo hundred and eighty six formalin fixed, paraffin 
embedded tissue block samples from the breast lesions 
were investigated. These included 262 (92%) invasive 
ductal carcinomas, 13 (4.6%) invasive lobular carcinomas, 
6 (2.1%) invasive mucinous carcinomas, 2 (0.7%) invasive 
papillary carcinoma, 1 (0.4%) medullary carcinoma and 
1 (0.4%) mixed invasive ductal and lobular carcinoma 
(Table 1).
Eighty eight (31.1%) cases presented a tumour size of  
20mm, 102 (36.0%) presented a tumour size between 
20-50mm, and 93 (32.9%) presented a tumour size of  
50mm (Table 1). Thirty six (12.7%) cases were tumour 
grade I, 136 (48.0%) were tumour grade II, and 111 
(39.3%) were tumour grade III (Table 1). Only 51 (17.8%) 
cases were examined for lymph node positivity, with 42 
(82.4%) being positive and 9 (17.6%) being negative 
(Table 1).
Other factors including BMI were available for 42 
(14.8%) cases, with 5 (11%) being underweight, and 
larger proportions being either of normal weight 14 
(33.3%), overweight 13 (31%) or obese 10 (23.3%). The 
triple-negative phenotype was observed in 248 (87%) of eligible breast cancer cases, 20 (7%) were classified as ER-positive, 6 (2.1%) were classified as PR-positive, and 11 (3.9%) were classified as HER2-positive (Table 2) 
(Figure 1). 
The average age of presentation for ER/PR-positive cases 
was 51.3 years old whereas for HER2-positive and triple-
negative breast cancer was 48.1 and 48.8, respectively. 
Although ER/PR-positive breast cancer cases were 
associated with older age and HER2-positive and triple-negative with younger age, the diferences between the groups were not significant (Table 3). Tumour grade 
Table 1 Distribution of breast carcinoma by clinicopathological 
features (286 cases).
Clinicopathological features Frequency Percentage
Histological type (available for 285 (99. 6%)) 
Invasive ductal carcinoma 262 92% 
Invasive lobular carcinoma 13 4.6% 
Invasive mucinous carcinoma 6 2.1% 
invasive papillary carcinoma 2 0.7% 
Medullary carcinoma 1 0.4% 
Mixed Invasive ductal &
lobular carcinoma 
1 0.4% 
Total 285 100% 
Tumour size (available for 283 (98. 9%)) 
<2 cm 88 31.1% 
2-5 cm 102 36.0% 
>5 cm 93 32.9% 
Total 283 100% 
Tumour grade (available for 283 (98. 9%)) 
Grade I 36 12.7% 
Grade II 136 48.0% 
Grade III 111 39.3% 
Total 283 100% 
Lymph node status (available for 51 (17. 8%)) 
Negative 9 17.6% 
Positive 42 82.4% 
Total 51 100% 
Body mass index (BMI) (available for 42 (14.7%))
Underweight <18.5 5 11.9%
Normal 18.5-24.9 14 33.3%
Overweight 25-29.9 13 31.0%
Obese >30 10 23.80%
Total 42 100%
Table 2 Expression of ER, PR, and HER2 markers in breast carcinoma.
Marker Positive Negative
Cases (286) Frequency Percentage Frequency Percentage
ER 20 7.0% 266 93.0% 
PR 6 2.1% 280 97.9% 
HER2/neu 11 3.9% 275 96.2% 
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Figure 1 Positive expression of Immunohistochemical profiles in 
invasive breast cancer tissues. ER (A) and PR (B) are only present in the nucleus and HER2 (C) is mainly present in the cytoplasm. Magnification 
x100.was significantly associated with breast cancer receptor subtypes. A significant (P  0.019) proportion of grade I tumours were ER/PR-positive whereas a significant (P 
 0.009) proportion of grade II tumours were HER2-
positive (Table 3).Tumour size was also significantly associated with 
breast cancer receptor subtypes. Although there was no statistically significant diferences in expression for ER/
PR and HER2 in smaller tumour sizes ( 20mm), there was a significant (p  0.001) proportion of ER-positive tumours that were between 20-50mm and a significant 
(P  0.0001) proportion of HER2-positive and triple-
negative were associated with larger tumour sizes 
(50mm) (Table 3).
DiscussionOur findings revealed that a large number of breast 
cancer cases (87%) in Nigeria are triple-negative. Only 
7% of cases account for ER-positive, 2.1% account for 
PR-positive, and 3.8% for HER2-positive breast cancers. The immediate realisation of a possible misclassification 
in these samples arises from the high proportion of 
triple-negative (87%) and low proportion of ER (7%), 
PR (2.1%), and HER2 (3.8%). However, studies of breast 
cancer markers in Sub-Saharan Africa have had extremely variable findings with reported percentage of ER-negative 
tumours ranging from 40% [17], [20] to 70% [21, 22]. 
In comparison, corresponding percentages in the black 
American population were 35% in breast cancer patients 
aged 40 and 15% to 20% by age 70 [23]. A study carried 
out at the University of Michigan evaluated the pattern of 
ER, PR, HER2, and triple-negative breast cancers in white 
American, black American, Ghanaian/African background 
and showed a high prevalence of triple-negative breast 
cancers in Ghanaian women (82.2%) followed by black 
American (26.4%) and white American (16%) women 
[22].
The high prevalence of triple-negative breast cancer in the 
present study (87.0%) is in concordance with the reported 
data for the Ghanaian/African background in the Michigan 
study (82.2%) [22]. The prevalence of ER-positive and/
or PR-positive, and HER2-positive breast cancer in the 
Michigan study was 61.9% for white American, 49.4% for 
black American, and 13.3% for Ghanaian population [22]. 
Results for ER-positive and/or PR-positive, and HER2-
positive breast cancer in our study were 13.0%. Another 
study evaluating the hormone expression in East African 
breast cancer cases also showed poor ER and PR-positivity 
(24% and 10%, respectively) and high prevalence of 
triple-negative (66%) breast cancer [22].The IHC-based classification systems are still considered 
useful in clinical practice, especially when fresh tissue is 
not available and has been shown to correlate well with intrinsic classification using gene expression microarrays 
[24]. It is worth noting, however, that the reliability of the 
ER/PR and HER2 testing is imperfect. There are substantial 
Table 3 Baseline characteristics by tumour subtype.
ER/PR+ (26) HER2+ (12)
ER/PR-, 
HER2- (248)
p-value
Age (years) 51.3± 11.2 48.1±7.9 48.8± 12.7 0.593
Tumour grade 
 
I 
II 
III
6 (23.1%)* 
11 (42.3%) 
9 (34.6%) 
1 (9.1%) 
8 (72.7%)* 
2 (18.2%)*
29 (11.7%) 
119 (48.0%) 
100 (40.3%)
*<0.019 
*<0.009 
*<0.0001
Tumour size
 
<20mm 
20-50mm 
>50mm
9 (34.6%) 
15 (57.7%)* 
2 (7.7%)* 
4 (33.3%) 
4 (33.3%) 
3 (27.2%)
75 (30.2%) 
85 (34.3%) 
91 (36.7%) 
0.336 
*<0.001 
*<0.0001
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intra-laboratory and inter-laboratory variation in results because of fixation, antigen retrieval, and staining 
methods that may vary among laboratories [18]. The 
drawback of ER testing is that results are highly sensitive to biopsy-tissue fixation and processing procedures, 
which leads to false negatives worldwide [19]. Ideally, 
receptor status should be determined in biopsy specimen 
obtained before pre-operative neoadjuvant therapy with 
IHC performed shortly after to avoid antigen degradation 
[25]. Moreover, if receptor status is determined from 
mastectomy tissue taken after neoadjuvant chemotherapy, 
the tumour phenotype may no longer be the same. 
Substantial discordance has also been reported in HER2 results produced in diferent laboratories from the same 
specimen [18, 26]. The present study raises two issues of 
vital importance in studying the breast cancer subtypes. 
First, whether cancer tissue samples are processed, 
preserved and stained in line with international 
guidelines Having carried out a retrospective study, the 
second issue would be the lengthy storage of the tissue 
samples. The latter is a deterrent factor in determining 
breast cancer subtypes as it is widely known that IHC performs better on fresh samples and it is afected by the fixation methods, reagents used, protocols, antibody 
sensitivity, and scoring system [27]. Tissue samples used 
in this study were obtained from archived samples from 
2008 to 2011 and we do lack information on how tissues were fixed and processed. Such limitations suggest that possible misclassification may occur. Nonetheless, it is 
important to evaluate the breast cancer receptor status profile for this sample group in order to understand the 
possible limitations of this study and exercise ways to 
assist this Institute in establishing standards for molecular 
breast cancer diagnosis in the future.
 
Indeed, it was acknowledged that there will be misclassification in this retrospective study due to fixation and processing techniques as well as long-term 
storage and IHC staining methods. As a result, this breast cancer receptor classification study was complemented 
with other important clinical and prognostic variables for 
the individuals such as age, tumour size, tumour grade, 
and lymph node status [28]. The clinicopathological association data further affirms that the high proportion 
of triple-negative patients may be less associated with fixation, processing and storage techniques and more significantly associated with the biological nature of the 
tumours.
Stark and colleagues in 2010 demonstrated the impact 
of the racial/ ethnic composition in determining 
breast cancer receptor subtypes [22]. This study has 
demonstrated that the triple-negative subtype is not only 
associated with black African race but also tumour biology 
including tumour grade and size. ER/PR-positive breast cancer was significantly (P  0.019) associated with 
grade I tumours and tumour sizes  50mm (P  0.001). 
As previously reported ER-positive cancers are associated 
with a lower grade, smaller size, more likely to be node 
negative and better survival outcome than ER-negative 
cancers [7]. It has been demonstrated that ER expression 
decreased with increasing histological grade, indicating that the lower the tumour cell diferentiation, the lower the estrogen dependence, which would in turn afect the 
sensitivity to the hormone therapy [29-30]. Women with ER-positive breast cancer benefit from endocrine therapy 
explaining the better survival outcomes. Most evidence 
regarding the prognostic role of PR is based upon the 
assumption that PR expression indicates a functioning 
ER pathway [31]. Therefore, it has been shown that PR-
positive and ER-positive tumours have a better response 
to endocrine therapy than ER-positive and PR-negative 
cancers [32].
 HER2-positive were significantly (P  0.009) associated 
with grade II tumours but not with grade I or III; and significantly (P  0.0001) associated with larger tumours 
( 50mm). In a similar study the frequency of HER2 over expression decreased significantly in low grade tumour 
and also in patients with high grade tumour [33]. More 
recently, Lal et al., in a study of 3,655 breast cancer cases reported that HER2 amplification and over expression 
are limited essentially to invasive breast carcinoma of 
intermediate grade to high grade [34]. Under normal 
physiological conditions HER2 is inactive; however, once 
activated it may enhance tumour invasion and metastases 
and increase degree of malignancy [35], which may 
explain HER2 association with intermediate to high grade 
tumours and large tumour sizes. 
Triple-negative were more associated with grade II and grade III tumours and significantly (P  0.0001) associated 
with larger tumour sizes ( 50mm). These pathological 
features translate into poorer clinical prognosis and the 
worst overall and disease-free survival. Histologically, triple-negative breast cancers are poorly diferentiated 
and are characterized by an aggressive clinical history. Since there are no specific treatment guidelines for this 
subtype, triple-negative breast cancers are managed with 
standard treatment, which leaves them with a high rate of 
local and systemic relapse [36]. Therefore, this continues 
to direct the focus of ongoing research and it should be of great benefit to breast cancer patients of African 
background.
Conclusion
This study has supported the use of Immunohistochemistry classification as a clinical tool in the future as ER/PR 
and HER2 markers are widely available at a reasonable 
cost. This information is clinically useful, therapeutically informative and somewhat predictive. Additional eforts 
to translate the currently standardised research method 
into reliable and reproducible diagnostic protocols are 
ongoing. 
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